Navigation Links
FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility
Date:6/29/2011

ww.dendreon.com/.

www.dendreon.com

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves New Device to Treat Brain Aneurysms
2. European Commission Approves DuPont Tender Offer to Acquire Danisco
3. New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test
4. European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
5. FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy
6. European Union Approves Maize with Herculex® I/Herculex® RW and Herculex® RW/ Herculex® I/Roundup Ready® Corn 2 Trait Stacks for Import, Food, Feed & Processing
7. FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests
8. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
9. FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
10. European Union Approves Corn Stack with Herculex RW and Roundup Ready 2 Traits for Food, Feed, Import and Processing
11. EU Committee Approves New Food Applications for Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Tris Pharma, a specialty pharmaceutical ... announced that it has been selected as an award ... 2014 Awards for Excellence competition in the ... panel of judges from SCORE (Counselors to America,s Small ... be honored at a gala event to be held ...
(Date:8/27/2014)... After the boom of the energy ... beverage craze is going to be the stress relief ... use Stress Relief energy pattern which can be applied ... a beverage, including minerals, herbs and liquids. Stress Relief ... power into rapid recovery and helping to adapt more ...
(Date:8/27/2014)... August 27, 2014 WriteResult, LLC – ... has once again shown superiority when it comes to ... completing the ePRO portion of their most recent study ... Japan-based pharma chose WriteResult’s digital writing platform to collect ... the first to complete drew data from a number ...
(Date:8/26/2014)... , Aug. 26, 2014  NeuroSigma, Inc., a ... to develop bioelectronic technologies, today announced that it has ... U.S. Securities and Exchange Commission relating to a proposed ... of shares to be offered and the price range ... Jefferies LLC will act as the book-running ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Research Inc., (TSX:,ARI), a biotechnology company discovering and ... its financial and operational,results for the third quarter, ... of fiscal 2007 was one of preparation as ... into human clinical trials in,2008, while also building ...
... N.C., Oct. 12 Campbell Alliance, the leading,management ... today announced that Ben Bonifant, Vice President,of the ... at the Licensing Executive Society (LES) Annual Meeting. ... at the Vancouver Convention and,Exhibit Centre in Vancouver, ...
... 12 QuantiFERON(R)-TB Gold,In- Tube is Poised to ... for,Accurate & Effective Tuberculosis Screening October 12 ... controllers around the,country can now quickly and accurately ... Drug Administration (FDA) approval of,QuantiFERON(R)-TB Gold In-Tube (QFT(TM)). ...
Cached Biology Technology:ARIUS Announces Third Quarter Fiscal 2007 Financial Results 2ARIUS Announces Third Quarter Fiscal 2007 Financial Results 3ARIUS Announces Third Quarter Fiscal 2007 Financial Results 4ARIUS Announces Third Quarter Fiscal 2007 Financial Results 5ARIUS Announces Third Quarter Fiscal 2007 Financial Results 6ARIUS Announces Third Quarter Fiscal 2007 Financial Results 7ARIUS Announces Third Quarter Fiscal 2007 Financial Results 8ARIUS Announces Third Quarter Fiscal 2007 Financial Results 9ARIUS Announces Third Quarter Fiscal 2007 Financial Results 10ARIUS Announces Third Quarter Fiscal 2007 Financial Results 11ARIUS Announces Third Quarter Fiscal 2007 Financial Results 12ARIUS Announces Third Quarter Fiscal 2007 Financial Results 13ARIUS Announces Third Quarter Fiscal 2007 Financial Results 14ARIUS Announces Third Quarter Fiscal 2007 Financial Results 15Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver 2Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver 3Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 2Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 3
(Date:8/27/2014)... advocates, campaigns against trans-fats have largely succeeded in ... aim at sugar for its potential contributions to ... still wrangling over the best way to assuage ... article in Chemical & Engineering News ... Chemical Society. , In the article, Stephen Ritter, ...
(Date:8/27/2014)... factors thought to be associated with outcomes after ... age of the patient, mechanism of injury, nerve ... method, operation technique, and repair materials. However, despite ... peripheral nerve injuries, there is no agreement regarding ... the dose-effect relationship of the predictors has not ...
(Date:8/27/2014)... hours ago the Happy Camp Complex of fires had ... July complex had consumed 35,530 as of eight hours ... the Happy Camp Ranger District of the Klamath National ... August 11, 2014. All but three of those fires ... list of contained fires and their size at containment: ...
Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2
... a heart attack. But the damage to heart muscle is ... the most common cause of death in developed countries. ... body can,t do: mending broken hearts. Engineers and physicians at ... the growth and integration of stem cell-derived cardiac muscle cells. ...
... RIVERSIDE, Calif. Anthony Norman , a ... policy changes regarding people,s vitamin D daily intake ... to reducing the frequency of many diseases, including ... hypertension, cardiovascular disease, obesity and muscle weakness. ...
... German . , Those who have to fight ... physicists from different scientific fields have decided to cooperate with ... through heat treatment by means of magnetic nanoparticles on a ... to improve the success of the therapy. Within the scope ...
Cached Biology News:A strategy to fix a broken heart 2A strategy to fix a broken heart 3Biochemist proposes worldwide policy change to step up daily vitamin D intake 2Biochemist proposes worldwide policy change to step up daily vitamin D intake 3How many nanoparticles heat the tumor? 2How many nanoparticles heat the tumor? 3
Rabbit Serum New Zealand or California Origin...
... Customer Peptide Synthesis , Containing one Phospho-Amino Acid ... be returned to customer conjugation of peptide to KLH protein ... 102 days/each , Pre-immune bleed x1 /each ... , Test bleed (app. 5 ml) x1 /each ...
...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Biology Products: